IP Library Granted Patent US 9,102,915
Granted Patent B2
US 9,102,915 · App. 11/939,360 · Granted Aug 11, 2015

In vitro expansion of postpartum-derived cells using microcarriers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,915
App. No.
11/939,360
Granted
Aug 11, 2015
Kind
B2
Abstract

Compositions and methods for the growth and expansion of mammalian cells in culture are provided. In particular, methods for the growth and expansion of postpartum-derived cells in vitro are provided using surfaces such as microcarrier beads.

Claims (30)

1. A method of culturing anchorage-dependent postpartum-derived cells comprising:

providing at least one anchorage-dependent postpartum-derived cell;

providing a cell growth medium for growing the postpartum-derived cell;

providing at least one microcarrier for attachment of the anchorage-dependent postpartum-derived cell;

contacting and culturing the anchorage-dependent cell with the microcarrier in the presence of the growth medium under conditions permitting attachment and growth of the cell, wherein the conditions permitting attachment and growth of the cell comprise constant stirring at microcarrier culture initiation and during culturing,

wherein the resulting cultured cell is phenotypically the same as corresponding anchorage-dependent postpartum-derived cells grown in static cultures for all of the following markers: CD 10, CD 13, CD31, CD34, CD44, CD45, CD73, CD90, CD117, CD141, PDGFr-α, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, and HLA-DQ; and

wherein the postpartum-derived cell is selected from the group consisting of an umbilical derived cell and a placental derived cell.

2. The method of claim 1 , wherein the cells are umbilical derived cells.

3. The method of claim 1 , wherein the cells are placental derived cells.

4. The method of claim 1 wherein the microcarrier contains a bioactive agent.

5. The method of claim 1 further comprising a second cell type co-cultured with said anchorage-dependent postpartum-derived cells.

6. The method of claim 1 wherein the microcarrier is comprised of a material selected from the group consisting of glass, ceramic, metal, polystyrene, poly(monostearoylglyceride co-succinic acid), poly-D,L-lactide-co-glycolide, and sodium hyaluronate.

7. The method of claim 1 wherein the microcarrier is protein free.

8. The method of claim 1 wherein the microcarrier comprises a textured surface.

9. The method of claim 1 wherein the microcarrier possesses a microcurrent or is paramagnetic.

10. The method of claim 1 wherein the microcarrier is porous.

11. The method of claim 10 wherein the porous microcarrier is comprised of a material selected from the group consisting of glass, ceramic, metal, polystyrene, poly(monostearoylglyceride co-succinic acid), poly-D,L-lactide-co-glycolide, and sodium hyaluronate.

12. The method of claim 10 wherein the porous microcarrier is protein free.

13. The method of claim 10 wherein the porous microcarrier comprises a textured surface.

14. The method of claim 10 wherein the porous microcarrier is uncoated.

15. The method of claim 10 wherein the porous microcarrier is coated with poly(monostearoylglyceride co-succinic acid), poly-D,L-lactide-co-glycolide, sodium hyaluronate, fibronectin, laminin, elastin, lysine, n-isopropyl acrylamide, vitronectin, or collagen.

16. The method of claim 1 wherein the phenotype of the cultured cells comprises CD10+, CD13+, CD31−, CD34−, CD44+, CD45−, CD73+, CD90+, CD117−, CD141−, PDGFr-α+, HLA-A+, HLA-B+, HLA-C+, HLA-DR-, HLA-DP-, and HLA-DQ-.

17. The method of claim 1 which results in at least about five population doublings over about twenty days.

18. The method of claim 1 wherein the doubling time for the population is less than about 100 hours.

19. The method of claim 18 wherein the doubling time for the population is less than about 70 hours.

20. The method of claim 1 wherein conditions which permit attachment and growth of the anchorage-dependent postpartum-derived cell comprise a temperature of about 37° C.

21. The method of claim 20 wherein conditions further comprise a spinner flask or bioreactor.

22. The method of claim 1 wherein the cell growth medium comprises a serum concentration from about 7% to about 15%.

23. The method of claim 1 wherein the microcarrier is uncoated.

24. The method of claim 1 wherein the microcarrier is coated with poly(monostearoylglyceride co-succinic acid), poly-D,L-lactide-co-glycolide, sodium hyaluronate, fibronectin, laminin, elastin, lysine, n-isopropyl acrylamide, vitronectin, or collagen.

Assignments (8)
MERGER Recorded Jun 22, 2015
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: DEPUY ORTHOPAEDICS, INC.
Reel/Frame 035875/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2015
From: DEPUY ORTHOPAEDICS, INC.
To: DEPUY SPINE, INC.
Reel/Frame 035986/0799 →
CHANGE OF NAME Recorded Jun 22, 2015
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 035994/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2015
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS, LLC
Reel/Frame 035994/0783 →
CHANGE OF NAME Recorded Jun 22, 2015
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 035994/0824 →
CHANGE OF NAME Recorded Jun 22, 2015
From: HAND INNOVATIONS, LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 035994/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INCORPORATED
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026291/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2008
From: HARMON, ALEXANDER M.; HONG, L.S. KLAUDYNE; KIHM, ANTHONY J.; GOSIEWSKA, ANNA
To: ETHICON, INCORPORATED
Reel/Frame 020697/0917 →